Ann: Patrys CEO Presents at BIO Investor Forum , page-19

re: Ann: Patrys CEO Presents at BIO Investor ... My mistake . On 5th Nov 2010 Patrys announced that. FDA had granted orphan status for PAT-SC1 for 7 years. This makes the share price even more perplexing as we have a company that has orphan status granted for 2 products on 2 continents . A hopeless case of multiple myeloma has apparently been cured for about 170 days?
Add to this that a prestigious Medical institution gave Patrys a 500,000 euro grant on the quality of it's work makes the share price even more of a mystery. Nothing, let me repeat, NOTHING, happens without a cause. Perhaps the CEO can offer an explanation, preferably plausible.